Immunoinflammatory Regulation of Esketamine in Septic Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Studies have shown that excessive systemic inflammatory response and concomitant
immunosuppression are the main cause of early death in patients with sepsis. Therefore, it is
very important to reduce excessive inflammation and improve immunosuppression in the acute
phase of sepsis. Clinical studies have shown that esketamine combined with propofol for
sedation has been proven to be safe and effective for septic patients in the ICU due to its
cardiovascular stability. Previous studies have demonstrated that esketamine has
anti-inflammatory effects against depression and surgical stress. Our preliminary
experimental studies have found that esketamine had strong anti-inflammatory effects in the
acute phase of sepsis. However, it is not clear whether esketamine could reduce excessive
inflammation and improve immunosuppression in septic patients primarily sedated with a
continuous infusion of propofol.
This intervention study is to investigate whether three consecutive days of intravenous
esketamine infusions via infusion pump (0.07 mg/kg/h) could reduce excessive inflammation and
improve immunosuppression in septic patients requiring mechanical ventilation in the ICU
under sedation primarily with propofol.